Navigation Links
Oramed Submits Pre-IND Package to FDA for ORMD-0901 (oral exenatide), an Oral GLP-1 Analog for the Treatment of Type 2 Diabetes
Date:9/3/2013

JERUSALEM, September 3, 2013 /PRNewswire/ --

Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, announced today that it has submitted a pre-Investigational New Drug (pre-IND) package to the U.S. Food and Drug Administration (FDA) for ORMD-0901, an orally administered exenatide capsule.  Oramed's pre-IND package submission follows its recently announced meeting request letter submitted to the FDA.

The submitted pre-IND package provides the FDA with information on Oramed's ORMD-0901 research conducted to-date, as well as a clinical trial outline for a proposed U.S. clinical trial. The FDA's response to the pre-IND package will serve as a guide to the Company for product development and preparation of a full IND application.  

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines currently delivered via injection. Established in 2006, Oramed's technology is based on over 30 years of research by top research scientists at Jerusalem's Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801) currently initiating Phase 2 clinical trials on patients with type 2 diabetes (T2DM) under an Investigational New Drug application with the U.S. Food and Drug Administration, and with its oral exenatide capsule (ORMD-0901; a GLP-1 analog), with trials on healthy volunteers (Phase 1b) and T2DM patients (Phase 2a) underway. Oramed is also moving forward with clinical trials of ORMD-0801 for the treatment of type 1 diabetes. The company's corporate and R&D headquarters are based in Jerusalem.

For more information, the content of which is not part of this press release, please visit http://www.oramed.com

Forward-looking statements: This press release contains forward-looking statements. For example, we are using forward-looking statements when we discuss our clinical trials, revolutionizing the treatment of diabetes with our products, and ORMD-0901 being a more patient-friendly form of treatment or it addressing a significant market. These forward-looking statements are based on the current expectations of the management of Oramed only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for our product candidates; competition from other pharmaceutical or biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in launching our clinical trials; changes in legislation; inability to timely develop and introduce new technologies, products and applications; lack of validation of our technology as we progress further and lack of acceptance of our methods by the scientific community; inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; greater cost of final product than anticipated; loss of market share and pressure on pricing resulting from competition; laboratory results that do not translate to equally good results in real settings; our patents may not be sufficient; and final that products may harm recipients, all of which could cause the actual results or performance of Oramed to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Oramed undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Oramed, reference is made to Oramed's reports filed from time to time with the Securities and Exchange Commission.

Company Contact:
Oramed Pharmaceuticals
Aviva Sherman
Cell:   +972-54-792-4438
Office: +972-2-566-0001       
Email: aviva@oramed.com 


'/>"/>
SOURCE Oramed Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Oramed CEO to be Panelist at BIO International Convention Breakout Session on Israel Becoming Biotech Leader
2. Oramed Pharmaceuticals Moves Forward with Investigational New Drug Application for Oral Insulin
3. Bioassociate Announces Initiation of Coverage on Oramed Pharmaceuticals, Inc.
4. Oramed Pharmaceuticals Announces Reverse Stock Split
5. Oramed Pharmaceuticals Granted 2nd Patent in New Zealand; 3rd Patent for Core Technology on Oral Delivery of Proteins
6. Marrone Bio Innovations Submits New Bioherbicide for EPA Registration
7. Janssen Submits Additional Marketing Applications for ZYTIGA® in the U.S. and European Union
8. iBio, Inc. Submits Plan to Satisfy NYSE Amex Continued Listing Standards
9. WellnessFX Launches New Products e-HealthAnswers and Womens Fertility Package
10. XY Precision Positioning Stage Provides Nanometer Incremental Motion in a Small Package: PI introduces Affordable 2-Axis Piezo Positioner, Model P-763
11. FDA/PhUSE Collaboration: Study Data Reviewer’s Guide Work Package v1.1 Available
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... ... 27, 2016 , ... The Board of Directors of Biohaven ... Tilton as Chief Commercial Officer.  Mr. Tilton joined Biohaven from Alexion Pharmaceuticals, Inc. ... responsible for the commercialization of multiple orphan drug indications. Mr. Tilton has ...
(Date:4/27/2016)... MD (PRWEB) , ... April 27, 2016 , ... ... Greg Lamka, PhD to its Scientific Advisory Board. Dr. Lamka will assist PathSensors ... plant pathogen detection. , PathSensors deploys the CANARY® test platform for the ...
(Date:4/27/2016)... ... April 27, 2016 , ... Global Stem Cells Group CEO Benito ... the founder of GSCG affiliate Kimera Labs in Miami. , In 2004, Ross received ... cell transplantation for hematologic disorders and the suppression of graft vs. host disease (GVHD) ...
(Date:4/27/2016)... April 27, 2016 MedDay, a biotechnology ... announces the appointment of Catherine Moukheibir as Chairman of its ... Chairman, Jean Jacques Garaud , who contributed to the ... effective immediately. Catherine started her career in strategy ... and London .  She held C-Suite level ...
Breaking Biology Technology:
(Date:3/22/2016)... PROVO and SANDY, ... Screening Ontario (NSO), which operates the highest sample volume ... testing, and Tute Genomics and UNIConnect, leaders in clinical ... today announced the launch of a project to establish ... testing panel. NSO has been contracted ...
(Date:3/17/2016)... -- ABI Research, the leader in transformative technology ... will reach more than $30 billion by 2021, ... electronics, particularly smartphones, continue to boost the biometrics ... two billion shipments by 2021 at a 40% ... Analyst at ABI Research. "Surveillance is also gearing ...
(Date:3/14/2016)... Florida , March 14, 2016 ... the growing mobile commerce market, announces the airing of a ... channels starting the week of March 21 st .  The ... CNBC, including its popular Squawk on the Street show. ... focused on the growing mobile commerce market, announces the airing ...
Breaking Biology News(10 mins):